1.Allen, JM. Economic/societal burden of metastatic breast cancer: A US perspective. Am J Manag Care. 2010;16:697–704.
2.Barron, JJ, Quimbo, R, Nikam, PT, Amonkar, MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109:367–377.
3.Bennett, CL, Calhoun, EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist. 2007;12:478–483.
4.Berkowitz, N, Gupta, S, Silberman, G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3:23–30.
5.Brewster, AM, Hortobagyi, GN, Broglio, KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179–1183.
6.Bureau of Labor Statistics. News release: The employment situation - April 2011. Washington, DC: U.S. Department of Labor; 2011.
7.Bureau of Labor Statistics. Table 22: Persons at work in nonagricultural industries by age, sex, race, Hispanic or Latino ethnicity, marital status, and usual full- or part-time status. U.S. Department of Labor; 2010.
8.Bureau of Labor Statistics & U.S. Census Bureau. Current Population Survey, Design and Methodology. Technical Paper TP63RV. Washington, DC: U.S. Department of Labor and U.S. Department of Commerce, Economics and Statistics Administration; 2010.
9.Campbell, JD, Ramsey, SD.The costs of treating breast cancer in the US: A synthesis of published evidence. Pharmacoeconomics. 2009;27:199–209.
10.Davis, KL, Iyer, S, Candrilli S. Predictors of the direct costs of breast cancer in the United States elderly population. Value Health. 2010;13:A260.
11.Elting, LS, Shih, YC. The economic burden of supportive care of cancer patients. Support Care Cancer. 2004;12:219–226.
12.Hartmann, LC, Zahasky, KM, Grendahl, DC. Management of cancer pain. Safe, adequate analgesia to improve quality of life. Postgrad Med. 2000;107:267–272, 75-76.
13.Hayman, JA, Langa, KM, Kabeto, MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001;19:3219–3225.
14.Kruse, GB, Amonkar, MM, Smith, G, et al. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008;14:844–857.
15.Kurian, AW, Thompson, RN, Gaw, AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25:634–641.
16.Lamerato, L, Havstad, S, Gandhi, S, et al. Economic burden associated with breast cancer recurrence: Findings from a retrospective analysis of health system data. Cancer. 2006;106:1875–1882.
17.Mauri, D, Polyzos, NP, Salanti, G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100:1780–1791.
18.Montazeri, A. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.
19.National Cancer Institute. Cancer trends progress report – 2009/2010 uapdate. Bethesda, MD: NIH, DHHS; April 2010.
20.National Cancer Institute. Surveillance Epidemiology and End Results (SEER) - Breast cancer. 2007–2010. Bethesda, MD: National Cancer Institute.
21.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2011. Fort Washington, PA: National Comprehensive Cancer Network.
22.Printz, C. Healthcare reform affects cancer on many fronts. More coverage for treatment and prevention planned. Cancer. 2010;116:3525–3526.
23.Rao, S, Kubisiak, J, Gilden, D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25–32.
24.Schwartz, J. Current combination chemotherapy regimens for metastatic breast cancer. Am J Health Syst Pharm. 2009;66 (Suppl 6):S3–S8.
25.Sloss, EM, Wickstrom, SL, McCaffrey, DF, et al. Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions. Cerebrovasc Dis. 2004;18:8–15.
26.Stokes, ME, Thompson, D, Montoya, EL, et al. Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-medicare data. Value Health. 2008;11:213–220.
27.Wang, SJ, Fuller, CD, Choi, M, Thomas, CR. A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointest Cancer Res. 2008;2:57–63.
28.Yabroff, KR, Lawrence, WF, Clauser, S, et al. Burden of illness in cancer survivors: Findings from a population-based national sample. J Natl Cancer Inst. 2004;96:1322–1330.